Aspen Investment Management Inc Purchases 1,774 Shares of Boston Scientific Corporation $BSX

Aspen Investment Management Inc lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 20.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,474 shares of the medical equipment provider’s stock after purchasing an additional 1,774 shares during the period. Aspen Investment Management Inc’s holdings in Boston Scientific were worth $1,125,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in BSX. Riverwater Partners LLC grew its holdings in Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after buying an additional 98 shares during the last quarter. IVC Wealth Advisors LLC boosted its position in shares of Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 102 shares during the period. HHM Wealth Advisors LLC grew its stake in shares of Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock worth $89,000 after acquiring an additional 103 shares during the last quarter. Rise Advisors LLC increased its position in Boston Scientific by 13.9% during the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 103 shares during the period. Finally, Sound View Wealth Advisors Group LLC raised its stake in Boston Scientific by 3.9% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 103 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE:BSX opened at $99.23 on Wednesday. The stock has a market capitalization of $147.10 billion, a P/E ratio of 53.06, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The firm has a 50 day moving average of $99.41 and a 200-day moving average of $102.51.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the company earned $0.63 EPS. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 175,782 shares of company stock valued at $17,742,314. 0.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

BSX has been the topic of several research analyst reports. Morgan Stanley raised their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Barclays boosted their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Wells Fargo & Company raised their price objective on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Canaccord Genuity Group restated a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.